Vericiguat (BAY1021189) 5 mg

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Chronic Heart Failure With Reduced Ejection Fraction

Clinical Trial

Last updated: 1/6/2026

Developer

BAYRY

BAYER

Related Pipeline

Colorectal Neoplasms

Pneumonia, Bacterial

Overactive Bladder

Chronic Kidney Disease

Oral Contraceptive